Chapter

Chemoprevention

Shaheenah Dawood and Jack Cuzick

in Endocrine Therapies in Breast Cancer

Published on behalf of Oxford University Press

ISBN: 9780199218141
Published online May 2011 | e-ISBN: 9780199606993 | DOI: http://dx.doi.org/10.1093/med/9780199218141.003.0009

Series: Oxford Oncology Library

Chemoprevention

Show Summary Details

Preview

• Factors associated with an increased risk of developing breast cancer include older age, early menarche, previous history of breast biopsies, obesity, BRAC1/2 mutations, a previous history of breast cancer and DCIS/LCIS. • Potential clinical biomarkers that can assess breast cancer risk include mammographic density and serum oestrogen level. • Tamoxifen and Raloxifen reduce the risk of oestrogen receptor-positive breast cancer by approximately 50%. • Aromatase inhibitors are currently being investigated as potential primary chemopreventive agents. • The role of agents such as cyclooxygenase-2 inhibitors, NSAIDs, statins and tyrosine kinase inhibitors in reducing oestrogen receptor-negative breast cancer are currently being investigated.

Chapter.  6627 words. 

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.